Updates on Legal Developments in the EU Life Sciences Industry
Article originally published in Competition Law Insight on November 25, 2008
May a dominant pharmaceutical company refuse to supply in full the orders it receives from a wholesaler in an EU member state in order to limit parallel trade in its products in the European Union? This was the question addressed by the European Court …
Article originally published in PLC Cross-border Life Sciences Handbook, 2007/08
Apart from patent disputes linked to generic entry, perhaps no issue has spawned more litigation in the European pharmaceutical sector than parallel trade. At the root of the problem are price differences among member states for pharmaceutical products which are caused by national price controls.…
Article originally published in the Cross-border Life Sciences Handbook 2006/07
Pharmaceutical and biotech companies are turning with increasing frequency to in-licensing and collaboration agreements – pharmaceutical companies to put new products in their pipelines and biotech companies to access the resources needed for final-stage development, clinical trials, manufacturing, and distribution. One result of the increasing…
Originally published as Covington Life Sciences Alert on June 1st, 2005
May a dominant pharmaceutical company refuse to supply in full the orders it receives from a wholesaler in an EU country in order to limit parallel trade in its products in the European Union? This was the question put to the European Court of…
